<DOC>
	<DOCNO>NCT02477475</DOCNO>
	<brief_summary>The objective investigation collect follow data patient give NEXIUM capsule ( NEXIUM ) usual post-marketing use .</brief_summary>
	<brief_title>Nexium Capsules S-CEI Justification Esomeprazole Acid Related Disease Reflux Symptom Healing Based Patient Clinical Outcomes</brief_title>
	<detailed_description>Primary objective To investigate treatment response NEXIUM patient reflux esophagitis ( RE ) . Secondary objective To investigate following item patient RE : 1 . Patient satisfactory level treatment RE 2 . Health-related quality life ( HRQOL ) 3 . Severity frequency RE symptom report physician 4 . Endoscopic heal rate 5 . Development ADRs</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Esophagitis , Peptic</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Patients enrol SCEI must fulfill criterion start treatment NEXIUM . 1 . Aged least 20 year . 2 . Patients current past history clinically diagnose RE 3 . Patients whose answer baseline GerdQ include `` 23 day '' `` 47 day '' least one question Nos 1 , 2 , 5 6 . 4 . Patients NEXIUM 20 mg daily administer RE 5 . Patients write consent obtain . Patients must enter investigation follow exclusion criterion fulfil start treatment NEXIUM : 1 . Patients whose ability follow instruction suspect low physician 2 . Patients past history hypersensitivity ingredient NEXIUM . 3 . Patients receive atazanavir sulfate rilpivirine hydrochloride 4 . Patients receive NEXIUM within past eight week treatment RE</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>reflux esophagitis</keyword>
	<keyword>Nexium</keyword>
</DOC>